Recognition and Management of Graft Versus Host Disease

Graft versus host disease (GVHD) is a serious complication that increases mortality and significantly impacts quality of life in allogeneic HCT recipients.  A thorough understanding of the various clinical manifestations of acute and chronic GVHD is essential for the early recognition of signs and symptoms. Oncology nurses require ongoing education that provides expert guidance necessary for the optimal management of patients with GVHD. Care of patients with GVHD requires additional knowledge on side effects, patient assessments, laboratory tests, treatment administration, and acute or intensive care.  Nursing care of patients with skin GVHD should be determined by the degree of severity and percentage of body surface area of the rash with specific considerations made regarding hygiene, topical and systemic treatment, infection prevention and relief of symptoms. Nursing care of patients with GI GVHD should include accurate recording of intake and output, obtaining cultures, monitoring for fluid and electrolyte imbalances, nutrition assessments, and managing side effects of treatments. Management of complications of GVHD treatments, namely the effects of prolonged exposure to corticosteroids, requires experts from many disciplines to provide comprehensive care. Therefore, management of GVHD can be optimized by providing coordinated care involving a multidisciplinary team which includes oncology nurses trained in the specialized care of GVHD patients.

Target Audience

This educational program is designed to meet the educational needs of oncology nurses who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Recognize acute and chronic GVHD symptoms
  • Describe medical and supportive care approaches for management of GVHD 
  • Identify methods for improving the quality of life in patients with GVHD
Additional information

This activity is supported by educational grants from:

  • AstraZeneca
  • Genentech, a member of the Roche Group
  • Novartis
  • Pfizer Inc.
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Taiho Oncology, Inc.

This activity is supported by independent medical education grants from:

  • Bristol-Myers Squibb
  • Celgene Corporation

This activity is supported by independent educational grants from:

  • AbbVie
  • Incyte
  • Merck & Co., Inc.
Course summary
Available credit: 
  • 1.00 ANCC contact hours
  • 1.00 Participation
Course opens: 
Course expires: 

Erin Kopp, ACNP-BC
City of Hope National Medical Center


NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers  
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures
The faculty listed below discloses the following relevant financial relationships:
Erin Kopp, DNPc, ACNP-BC
Incyte Corporation: Product/Speakers Bureau
Kyowa Hakko Kirin Co., Ltd.: Product/Speakers Bureau

NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein

The NCCN Clinical staff listed below discloses no relevant financial relationships:
Lenora Pluchino, PhD

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NCCN designates this educational activity for a maximum of 1.0 contact hour.

Available Credit

  • 1.00 ANCC contact hours
  • 1.00 Participation


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: